Skip to main content
Top
Published in: Acta Diabetologica 2/2013

Open Access 01-04-2013 | Review Article

Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update

Authors: Francesco Piarulli, Giovanni Sartore, Annunziata Lapolla

Published in: Acta Diabetologica | Issue 2/2013

Login to get access

Abstract

Diabetes is associated with a greatly increased risk of cardiovascular disease (CVD), which cannot be explained only by known risk factors, such as smoking, hypertension, and atherogenic dyslipidemia, so other factors, such as advanced glycation end-products (AGEs) and oxidative stress, may be involved. In this frame, hyperglycemia and an increased oxidative stress (AGE formation, increased polyol and hexosamine pathway flux, and protein kinase C activation) lead to tissue damage, thus contributing to the onset of cardiovascular complications. Several studies have identified in various cell systems, such as monocytes/macrophages and endothelial cells, specific cellular receptors (RAGE) that bind AGE proteins. The binding of AGEs on RAGE induces the production of cytokines and intracellular oxidative stress, thus leading to vascular damage. Soluble RAGE levels have been identified as hypothetical markers of CVD, but, in this regard, there are sparse and conflicting data in the literature. The purpose of this review was to examine all the available information on this issue with a view to clarifying or at least highlighting the points that are still weak, especially from the point of clinical view.
Literature
1.
go back to reference Diabetes Vital Statistics (1996) American Diabetes Association, Virginia Diabetes Vital Statistics (1996) American Diabetes Association, Virginia
2.
go back to reference Jay RH, Betteridge DJ (1994) The heart and macrovascular disease in diabetes mellitus. In: Pickup JC, Williams G (eds) Chronic complications of diabetes. Blackwell Press, Melbourne, pp 195–212 Jay RH, Betteridge DJ (1994) The heart and macrovascular disease in diabetes mellitus. In: Pickup JC, Williams G (eds) Chronic complications of diabetes. Blackwell Press, Melbourne, pp 195–212
3.
go back to reference Pyorala K, Laakso M, Uusitupa M (1987) Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3:463–524PubMedCrossRef Pyorala K, Laakso M, Uusitupa M (1987) Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3:463–524PubMedCrossRef
4.
go back to reference Yegin A, Ozben T, Yegin H (1995) Glycation of lipoproteins and accelerated atherosclerosis in non-insulin-dependent diabetes mellitus. Int J Clin Lab Res 25:157–161PubMedCrossRef Yegin A, Ozben T, Yegin H (1995) Glycation of lipoproteins and accelerated atherosclerosis in non-insulin-dependent diabetes mellitus. Int J Clin Lab Res 25:157–161PubMedCrossRef
5.
go back to reference Imanaga Y, Sakata N, Takebayashi S, Matsunaga A, Sasaki J, Arakawa K, Nagai R, Horiuchi S, Itabe H, Takano T (2000) In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis 150:343–355PubMedCrossRef Imanaga Y, Sakata N, Takebayashi S, Matsunaga A, Sasaki J, Arakawa K, Nagai R, Horiuchi S, Itabe H, Takano T (2000) In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis 150:343–355PubMedCrossRef
7.
go back to reference Kuyvenhoven JP, Meinders AE (1999) Oxidative stress and diabetes mellitus: pathogenesis of long-term complications. Eur J Int Med 10:9–19CrossRef Kuyvenhoven JP, Meinders AE (1999) Oxidative stress and diabetes mellitus: pathogenesis of long-term complications. Eur J Int Med 10:9–19CrossRef
8.
go back to reference Lapolla A, Piarulli F, Sartore G, Rossetti C, Martano L, Carraro P, De Paoli M, Fedele D (2003) Peripheral artery disease in type 2 diabetes: the role of fibrinolysis. Thromb Haemost 89:91–96PubMed Lapolla A, Piarulli F, Sartore G, Rossetti C, Martano L, Carraro P, De Paoli M, Fedele D (2003) Peripheral artery disease in type 2 diabetes: the role of fibrinolysis. Thromb Haemost 89:91–96PubMed
9.
go back to reference Vlassara H, Palace MR (2002) Diabetes and advanced glycation end products. J Intern Med 251:87–101PubMedCrossRef Vlassara H, Palace MR (2002) Diabetes and advanced glycation end products. J Intern Med 251:87–101PubMedCrossRef
10.
go back to reference Yan SF, Ramasamy R, Naka Y, Schmidt AM (2003) Glycation, inflammation and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93:1159–1169PubMedCrossRef Yan SF, Ramasamy R, Naka Y, Schmidt AM (2003) Glycation, inflammation and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93:1159–1169PubMedCrossRef
11.
go back to reference Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582–592PubMedCrossRef Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582–592PubMedCrossRef
12.
go back to reference Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 4:813–820CrossRef Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 4:813–820CrossRef
13.
go back to reference Giuliano D, Ceriello A, Paolisso G (1996) Oxidative stress and diabetic vascular complications. Diabetes Care 19:257–267CrossRef Giuliano D, Ceriello A, Paolisso G (1996) Oxidative stress and diabetic vascular complications. Diabetes Care 19:257–267CrossRef
14.
go back to reference Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products and the biochemical basis of diabetic complications. N Engl J Med 318:1315–1321PubMedCrossRef Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products and the biochemical basis of diabetic complications. N Engl J Med 318:1315–1321PubMedCrossRef
15.
go back to reference Thornalley PJ (1996) Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab 3:149–166 Thornalley PJ (1996) Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab 3:149–166
16.
go back to reference Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1–9PubMedCrossRef Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1–9PubMedCrossRef
17.
go back to reference Lapolla A, Fedele D, Traldi P (2001) Diabetes and mass spectrometry. Diabetes Metab Res Rev 17(2):99–112PubMedCrossRef Lapolla A, Fedele D, Traldi P (2001) Diabetes and mass spectrometry. Diabetes Metab Res Rev 17(2):99–112PubMedCrossRef
18.
go back to reference Lapolla A, Gerhardinger G, Pelli B et al (1990) Absence of brown products FFI in non-diabetic and diabetic rat collagen. Diabetes 39:57–61PubMedCrossRef Lapolla A, Gerhardinger G, Pelli B et al (1990) Absence of brown products FFI in non-diabetic and diabetic rat collagen. Diabetes 39:57–61PubMedCrossRef
19.
go back to reference Lapolla A, Baldo L, Aronica R et al (1994) Matrix assisted laser desorption ionization mass spectrometric studies on protein glycation. The reaction of ribonuclease with hexoses. Biol Mass Spectrom 23:241–248CrossRef Lapolla A, Baldo L, Aronica R et al (1994) Matrix assisted laser desorption ionization mass spectrometric studies on protein glycation. The reaction of ribonuclease with hexoses. Biol Mass Spectrom 23:241–248CrossRef
20.
go back to reference Bucala R, Cerami A (1992) Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol 23:1–34PubMedCrossRef Bucala R, Cerami A (1992) Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol 23:1–34PubMedCrossRef
21.
go back to reference Lapolla A, Porcu S, Traldi P (2011) Some views on proteomics in diabetes. Clin Chem Lab Med 49(6):943–957PubMedCrossRef Lapolla A, Porcu S, Traldi P (2011) Some views on proteomics in diabetes. Clin Chem Lab Med 49(6):943–957PubMedCrossRef
22.
go back to reference Ahmed N, Babei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ (2005) Degradation products of protein damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48:1590–1603PubMedCrossRef Ahmed N, Babei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ (2005) Degradation products of protein damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48:1590–1603PubMedCrossRef
23.
go back to reference Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM (1999) N(epsilon)-carboxymethyllysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 44:31740–31749CrossRef Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM (1999) N(epsilon)-carboxymethyllysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 44:31740–31749CrossRef
24.
go back to reference Schleicher ED, Wagner E, Nerlich AG (1997) Increased accumulation of glycoxidation product carboxymethyllysine in human tissues in diabetes and aging. J Clin Invest 99:457–468PubMedCrossRef Schleicher ED, Wagner E, Nerlich AG (1997) Increased accumulation of glycoxidation product carboxymethyllysine in human tissues in diabetes and aging. J Clin Invest 99:457–468PubMedCrossRef
25.
go back to reference Yoshida N, Okumura K, Aso Y (2005) High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 54:345–350PubMedCrossRef Yoshida N, Okumura K, Aso Y (2005) High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 54:345–350PubMedCrossRef
26.
go back to reference Sell D, Lapolla A, Odetti P, Fogarty J, Monnier VM (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long-standing insulin-dependent diabetes mellitus. Diabetes 41:1286–1292PubMedCrossRef Sell D, Lapolla A, Odetti P, Fogarty J, Monnier VM (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long-standing insulin-dependent diabetes mellitus. Diabetes 41:1286–1292PubMedCrossRef
27.
go back to reference Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D (2007) Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 30:670–676PubMedCrossRef Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D (2007) Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 30:670–676PubMedCrossRef
28.
go back to reference Sing R, Barden A, Mori T, Beilin L (2001) Advanced glycation end products: a review. Diabetologia 44:129–146CrossRef Sing R, Barden A, Mori T, Beilin L (2001) Advanced glycation end products: a review. Diabetologia 44:129–146CrossRef
29.
go back to reference Giardino I, Edelstein D, Brownlee M (1994) Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: a model for intracellular glycosylation in diabetes. J Clin Invest 94:110–117PubMedCrossRef Giardino I, Edelstein D, Brownlee M (1994) Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: a model for intracellular glycosylation in diabetes. J Clin Invest 94:110–117PubMedCrossRef
30.
go back to reference Charonis AS, Reger LA, Dege JE, Kouzi-Koliakos K, Furcht LT, Wohlhueter RM, Tsilibary EC (1990) Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 39:807–814PubMedCrossRef Charonis AS, Reger LA, Dege JE, Kouzi-Koliakos K, Furcht LT, Wohlhueter RM, Tsilibary EC (1990) Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 39:807–814PubMedCrossRef
31.
go back to reference Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395–1403PubMedCrossRef Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395–1403PubMedCrossRef
32.
go back to reference Sakata N, Uesugi N, Takebayashi S, Nagai R, Jono T, Horiuchi S, Takeya M, Itabe H, Takano T, Myint T, Tamgiuchi N (2001) Glycoxidation and lipid peroxidation of low density lipoprotein can synergistically enhance atherogenesis. Cardiovasc Res 49:466–475PubMedCrossRef Sakata N, Uesugi N, Takebayashi S, Nagai R, Jono T, Horiuchi S, Takeya M, Itabe H, Takano T, Myint T, Tamgiuchi N (2001) Glycoxidation and lipid peroxidation of low density lipoprotein can synergistically enhance atherogenesis. Cardiovasc Res 49:466–475PubMedCrossRef
33.
go back to reference Moro E, Alessandrini P, Zambon C (1999) Is glycation of LDL in patients with type 2 diabetes mellitus a LDL pre-oxidative condition? Diabet Med 16(8):663–669PubMedCrossRef Moro E, Alessandrini P, Zambon C (1999) Is glycation of LDL in patients with type 2 diabetes mellitus a LDL pre-oxidative condition? Diabet Med 16(8):663–669PubMedCrossRef
34.
go back to reference Piarulli F, Lapolla A, Sartore G, Rossetti C, Bax G, Noale M, Minicuci N, Fiore C, Marchioro L, Manzato E, Fedele D (2005) Autoantibodies against oxidized LDLs and atherosclerosis in type 2 diabetes. Diabetes Care 28:653–657PubMedCrossRef Piarulli F, Lapolla A, Sartore G, Rossetti C, Bax G, Noale M, Minicuci N, Fiore C, Marchioro L, Manzato E, Fedele D (2005) Autoantibodies against oxidized LDLs and atherosclerosis in type 2 diabetes. Diabetes Care 28:653–657PubMedCrossRef
35.
go back to reference Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23:599–622PubMedCrossRef Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23:599–622PubMedCrossRef
36.
go back to reference Maxwell SR, Thomason H, Sandler D, Leguen C, Thorpe GH, Jones AF, Barnett AH (1997) Antioxidant status in patients with uncomplicated insulin-dependent and noninsulin-dependent diabetes mellitus. Eur J Clin Invest 271:484–490CrossRef Maxwell SR, Thomason H, Sandler D, Leguen C, Thorpe GH, Jones AF, Barnett AH (1997) Antioxidant status in patients with uncomplicated insulin-dependent and noninsulin-dependent diabetes mellitus. Eur J Clin Invest 271:484–490CrossRef
37.
go back to reference Stehouwer CDA (1997) von Willebrand factor, dysfunction of the vascular endothelium, and the development of renal and vascular complications in diabetes. In: Mogensen CE (ed) The kidney and hypertension in diabetes mellitus. Kluwer, Boston, pp 155–163 Stehouwer CDA (1997) von Willebrand factor, dysfunction of the vascular endothelium, and the development of renal and vascular complications in diabetes. In: Mogensen CE (ed) The kidney and hypertension in diabetes mellitus. Kluwer, Boston, pp 155–163
38.
go back to reference Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Nollino L, Cosma C, Fedele D, Lapolla A (2009) Relationship between glyco-oxidation, antioxidant status and microalbuminuria in type 2 diabetic patients. Diabetologia 52:1419–1425PubMedCrossRef Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Nollino L, Cosma C, Fedele D, Lapolla A (2009) Relationship between glyco-oxidation, antioxidant status and microalbuminuria in type 2 diabetic patients. Diabetologia 52:1419–1425PubMedCrossRef
39.
go back to reference Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products sparking the development of diabetic vascular injury. Circulation 114:597–605PubMedCrossRef Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products sparking the development of diabetic vascular injury. Circulation 114:597–605PubMedCrossRef
40.
go back to reference Schmidt AM, Hofmann M, Taguchi A, Yan SD, Stern DM (2000) RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost 26:485–493PubMedCrossRef Schmidt AM, Hofmann M, Taguchi A, Yan SD, Stern DM (2000) RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost 26:485–493PubMedCrossRef
41.
go back to reference Basta G (2008) Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 196:9–21PubMedCrossRef Basta G (2008) Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 196:9–21PubMedCrossRef
42.
go back to reference Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM (2009) RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20:742–752PubMedCrossRef Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM (2009) RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20:742–752PubMedCrossRef
43.
go back to reference Kalea AZ, Schmidt AM, Hudson BI (2009) RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 116:621–637CrossRef Kalea AZ, Schmidt AM, Hudson BI (2009) RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 116:621–637CrossRef
44.
45.
go back to reference Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097–1109PubMedCrossRef Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097–1109PubMedCrossRef
46.
go back to reference Vazzana N, Santilli F, Cuccurullo C, Davì G (2009) Soluble forms of RAGE in internal medicine. Int Emerg Med 4:389–401CrossRef Vazzana N, Santilli F, Cuccurullo C, Davì G (2009) Soluble forms of RAGE in internal medicine. Int Emerg Med 4:389–401CrossRef
47.
go back to reference Nawroth PP, Stern DM (2007) Soluble forms of RAGE: an index of vascular stress? A commentary on “Soluble RAGE in type 2 diabetes: association with oxidative stress”. Free Radical Biol Med 43:506–510 Nawroth PP, Stern DM (2007) Soluble forms of RAGE: an index of vascular stress? A commentary on “Soluble RAGE in type 2 diabetes: association with oxidative stress”. Free Radical Biol Med 43:506–510
48.
go back to reference Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, Bierhaus A (2007) sRAGE but not esRAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6:9–13PubMedCrossRef Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, Bierhaus A (2007) sRAGE but not esRAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6:9–13PubMedCrossRef
49.
go back to reference Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563–2569 Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563–2569
50.
go back to reference Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653 Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653
51.
go back to reference Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589PubMedCrossRef Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589PubMedCrossRef
53.
go back to reference Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R (1993) Immunohistochemical localization of advanced glycosylation endproducts (AGEs) in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 143:1649–1656PubMed Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R (1993) Immunohistochemical localization of advanced glycosylation endproducts (AGEs) in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 143:1649–1656PubMed
54.
go back to reference Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H (2001) Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85:87–91PubMedCrossRef Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H (2001) Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85:87–91PubMedCrossRef
55.
go back to reference Ahmed KA, Muniandy S, Ismail IS (2007) Role of Nε-(carboxymethyl)lysine in the development of ischemic heart disease in type 2 diabetes mellitus. J Clin Biochem Nutr 41:97–105CrossRef Ahmed KA, Muniandy S, Ismail IS (2007) Role of Nε-(carboxymethyl)lysine in the development of ischemic heart disease in type 2 diabetes mellitus. J Clin Biochem Nutr 41:97–105CrossRef
56.
go back to reference Gul A, Rathman MA, Salim A, Simjee SU (2008) Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complications. AGE 30:303–309PubMedCrossRef Gul A, Rathman MA, Salim A, Simjee SU (2008) Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complications. AGE 30:303–309PubMedCrossRef
57.
go back to reference Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L (2009) Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J Am Geriatr Soc 57:1874–1880PubMedCrossRef Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L (2009) Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J Am Geriatr Soc 57:1874–1880PubMedCrossRef
58.
go back to reference Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, Laakso M (2007) Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 50:1409–1417PubMedCrossRef Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, Laakso M (2007) Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 50:1409–1417PubMedCrossRef
59.
go back to reference Nin JWM, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving H-H, Tarnow L, Rossing P, Stehouwer CDA (2011) Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes. Diabetes Care 34:442–447PubMedCrossRef Nin JWM, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving H-H, Tarnow L, Rossing P, Stehouwer CDA (2011) Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes. Diabetes Care 34:442–447PubMedCrossRef
60.
go back to reference Lapolla A, Reitano R, Seraglia R, Sartore G, Ragazzi E, Traldi P (2005) Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress. Mol Nutr Food Res 49:685–690PubMedCrossRef Lapolla A, Reitano R, Seraglia R, Sartore G, Ragazzi E, Traldi P (2005) Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress. Mol Nutr Food Res 49:685–690PubMedCrossRef
61.
go back to reference Taki K, Tsuruta Y, Niwa T (2008) Cardiac troponin T and advanced glycation end-products in hemodialysis patients. Am J Nephrol 28:701–706PubMedCrossRef Taki K, Tsuruta Y, Niwa T (2008) Cardiac troponin T and advanced glycation end-products in hemodialysis patients. Am J Nephrol 28:701–706PubMedCrossRef
62.
go back to reference Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, Chen QJ, Shen WF (2009) Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205:544–548PubMedCrossRef Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, Chen QJ, Shen WF (2009) Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205:544–548PubMedCrossRef
63.
go back to reference Lu L, Pu LJ, Zhang Q, Wang LJ, Kang S, Zhang RY, Chen QJ, Wang JG, De Caterina R, Shen WF (2009) Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 206:540–545PubMedCrossRef Lu L, Pu LJ, Zhang Q, Wang LJ, Kang S, Zhang RY, Chen QJ, Wang JG, De Caterina R, Shen WF (2009) Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 206:540–545PubMedCrossRef
64.
go back to reference Peng WH, Lu L, Hu J, Yan XX, Zhang Q, Zhang RY, Chen QJ, Shen WF (2009) Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients. Clin Biochem 42:1252–1259PubMedCrossRef Peng WH, Lu L, Hu J, Yan XX, Zhang Q, Zhang RY, Chen QJ, Shen WF (2009) Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients. Clin Biochem 42:1252–1259PubMedCrossRef
65.
go back to reference Piarulli F, Ragazzi E, Sartore G, Reitano R, Nollino L, Cosma C, Sechi A, Fedele D, Lapolla A (2008) Role of endogenous secretory rage (esRAGE) in micro- and macro-vascular complications in a group of type 2 diabetic patients. Diabetes Vasc Dis Res 5:367–368 (abstract) Piarulli F, Ragazzi E, Sartore G, Reitano R, Nollino L, Cosma C, Sechi A, Fedele D, Lapolla A (2008) Role of endogenous secretory rage (esRAGE) in micro- and macro-vascular complications in a group of type 2 diabetic patients. Diabetes Vasc Dis Res 5:367–368 (abstract)
66.
go back to reference Basta G, Del Turco S, Marchi F, Navarra T, Battaglia D, Mercuri A, Mazzone A, Berti S (2011) Elevated soluble receptor for advanced glycation end product levels in patients with acute coronary syndrome and positive cardiac troponin I. Coron Artery Dis 22:590–594PubMedCrossRef Basta G, Del Turco S, Marchi F, Navarra T, Battaglia D, Mercuri A, Mazzone A, Berti S (2011) Elevated soluble receptor for advanced glycation end product levels in patients with acute coronary syndrome and positive cardiac troponin I. Coron Artery Dis 22:590–594PubMedCrossRef
67.
go back to reference Nin JWM, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving H-H, Tarnow L, Rossing P, Stehouwer CDA (2010) Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes. Diabetes 59:2027–2032PubMedCrossRef Nin JWM, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving H-H, Tarnow L, Rossing P, Stehouwer CDA (2010) Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes. Diabetes 59:2027–2032PubMedCrossRef
68.
go back to reference Park H-J, Baek J-Y, Shin WS, Kim D-B, Jang SW, Shin DI, Koh YS, Seo SM, Uhm J-S, Kim TH, Kim CJ, Kim PJ, Chang K, Chung WS, Seung K-B, Lee JM (2011) Soluble receptor of advanced glycated endproducts is associated with plaque vulnerability in patients with acute myocardial infarction. Circ J 75:1685–1690PubMedCrossRef Park H-J, Baek J-Y, Shin WS, Kim D-B, Jang SW, Shin DI, Koh YS, Seo SM, Uhm J-S, Kim TH, Kim CJ, Kim PJ, Chang K, Chung WS, Seung K-B, Lee JM (2011) Soluble receptor of advanced glycated endproducts is associated with plaque vulnerability in patients with acute myocardial infarction. Circ J 75:1685–1690PubMedCrossRef
69.
go back to reference Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, Charlton-Menys V, Bao W, DeMicco DA, Preston GM, Deshmukh H, Tan K, Fuller JH (2011) Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2. Diabetes 60:2379–2385PubMedCrossRef Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, Charlton-Menys V, Bao W, DeMicco DA, Preston GM, Deshmukh H, Tan K, Fuller JH (2011) Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2. Diabetes 60:2379–2385PubMedCrossRef
70.
go back to reference Chen G, Cai L, Chen B, Liang J, Lin F, Li L, Lin L, Yao J, Wen J, Huang H (2011) Serum level of endogenous secretory receptor for advanced glycation end products and other factors in type 2 diabetic patients with mild cognitive impairment. Diabetes Care 34:2586–2590PubMedCrossRef Chen G, Cai L, Chen B, Liang J, Lin F, Li L, Lin L, Yao J, Wen J, Huang H (2011) Serum level of endogenous secretory receptor for advanced glycation end products and other factors in type 2 diabetic patients with mild cognitive impairment. Diabetes Care 34:2586–2590PubMedCrossRef
71.
go back to reference Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques. Circulation 108:1070–1077PubMedCrossRef Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques. Circulation 108:1070–1077PubMedCrossRef
72.
go back to reference Yang SJ, Kim S, Hwang SY, Kim TN, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM (2012) Association between sRAGE, esRAGE levels and vascular inflammation: analysis with 18F-fluorodeoxyglucose positron emission tomography. Atherosclerosis 220:402–406PubMedCrossRef Yang SJ, Kim S, Hwang SY, Kim TN, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM (2012) Association between sRAGE, esRAGE levels and vascular inflammation: analysis with 18F-fluorodeoxyglucose positron emission tomography. Atherosclerosis 220:402–406PubMedCrossRef
73.
go back to reference Sartore G, Piarulli F, Ragazzi E, Burlina S, Chilelli NC, Sarais C, Marin R, Manzato E, Fedele D, Lapolla A (2011) Subclinical diastolic dysfunction in type 2 diabetic patients with and without carotid atherosclerosis: relationship with glyco-oxidation, lipid-oxidation and antioxidant status. Int J Cardiol. Jun 20 [Epub ahead of print] Sartore G, Piarulli F, Ragazzi E, Burlina S, Chilelli NC, Sarais C, Marin R, Manzato E, Fedele D, Lapolla A (2011) Subclinical diastolic dysfunction in type 2 diabetic patients with and without carotid atherosclerosis: relationship with glyco-oxidation, lipid-oxidation and antioxidant status. Int J Cardiol. Jun 20 [Epub ahead of print]
Metadata
Title
Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update
Authors
Francesco Piarulli
Giovanni Sartore
Annunziata Lapolla
Publication date
01-04-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 2/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-012-0412-3

Other articles of this Issue 2/2013

Acta Diabetologica 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine